Historical perspectives pertaining to the NIH Recombinant DNA Advisory Committee.
Science is host to a constantly emerging series of new paradigms, and it is this characteristic that makes science both interesting and dynamic. As a part of this continuum, it became possible to create recombinant DNA molecules. Immediately it was recognized that there was a potential for serious adverse events associated with this new technology. Following two scientific conferences at Asilomar, California, the National Institutes of Health moved quickly to create the Recombinant DNA Advisory Committee (RAC). For approximately 38 years the RAC has served as an open forum for review of various recombinant DNA experiments, and for the last 23 years it has played a pivotal role in the oversight of human gene therapy. The RAC's existence obviated the need for more restrictive governmental legislation and has supported the development of genetic interventions that are leading to actual human therapies.
Director of the NIH Office of Recombinant DNA Activities, Executive Director of the RAC, NIH, Bethesda, MD 20892; and Institute for Human Gene Therapy, University of Pennsylvania School of Medicine , Philadelphia, PA 19104.
Nelson A
NA
Wivel
D026683:Advisory Committees / Q000266:history; D004274:DNA, Recombinant; D015316:Genetic Therapy / Q000266:history / Q000331:legislation & jurisprudence / Q000592:standards; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D009316:National Institutes of Health (U.S.); D014481:United States
D004274:DNA, Recombinant